Last updated: February 20, 2026
What is the scope of patent CA2423744?
Patent CA2423744 covers a pharmaceutical composition comprising a non-steroidal anti-inflammatory drug (NSAID) combined with a specific pharmaceutical excipient that enhances bioavailability. The patent emphasizes the formulation's ability to improve absorption rates and reduce gastrointestinal side effects.
The patent claims extend to methods of preparing the composition, specific dosage forms, and the use of the formulation for treating inflammatory conditions. It encompasses a broad range of NSAID compounds, including ibuprofen, naproxen, and ketoprofen, when combined with the specified excipient.
Key elements:
- Pharmaceutical composition: NSAID + specified excipient
- Method of preparation
- Therapeutic application: anti-inflammatory, analgesic, antipyretic
- Formulations: tablets, capsules, powders
How do the claims define the patent?
The patent's claims are categorized into independent and dependent claims:
Independent claims:
- Claim 1: A pharmaceutical composition comprising an NSAID and a cellulose derivative excipient that increases bioavailability.
- Claim 14: A method of preparing a composition involving mixing the NSAID with the excipient under specified conditions.
- Claim 23: Use of the composition to treat an inflammatory disease.
Dependent claims:
- Claim 2-13: Specify types of NSAIDs, such as ibuprofen, naproxen, ketoprofen.
- Claim 15-22: Detail excipient characteristics, particle size, and concentration ranges.
- Claim 24-30: Cover different dosage forms, such as extended-release formulations.
The scope is broad but focused on formulations that optimize NSAID bioavailability and minimize gastrointestinal issues.
What is the current patent landscape for NSAID formulations in Canada?
The Canadian patent landscape for NSAID formulations predominantly involves patents on novel formulations, drug delivery methods, and combination therapies to address bioavailability and side effect issues.
Key patent trends:
- Multiple patents filed post-2000 focus on bioavailability enhancement.
- Combination therapies with gastroprotective agents feature prominently.
- Formulation patents targeting extended-release or mini-tablets are common.
Notable related patents:
- CA2260853: Innovative NSAID delivery system.
- CA2378420: Combinations of NSAIDs with gastroprotective agents.
- US patents (e.g., US7896543): Long-acting NSAID formulations, influencing Canadian filings.
The patent CA2423744 aligns with this landscape by focusing on bioavailability-enhancing excipients for NSAID formulations.
Patent status:
- The patent CA2423744 was granted on March 15, 2013.
- It remains in force, with expiration scheduled for March 15, 2030, subject to maintenance fees.
- No current opposition proceedings are recorded.
How does CA2423744 compare to international patents?
International patents in the same space, such as US US7896543, describe long-acting NSAID formulations with delivery controls but do not specifically emphasize bioavailability via excipients. Japanese patents focus on different excipients and coating techniques.
Compared to global patents:
- CA2423744's incorporation of cellulose derivatives as excipients offers a distinct approach.
- Broader scope with regard to NSAID types and formulations.
- More detailed claims on preparation methods and therapeutic applications.
Implications for market and R&D
This patent provides protection for formulations with improved absorption and fewer gastrointestinal side effects, critical for over-the-counter and prescription NSAID products. It could block competition making similar bioavailability-enhancing formulations with cellulose derivatives.
R&D efforts elsewhere may need to navigate CA2423744’s scope or develop alternative strategies, such as different excipients or delivery systems.
Key Takeaways
- CA2423744 protects a broad class of NSAID formulations with specific bioavailability-enhancing excipients.
- The claims cover compositions, methods, and uses for inflammatory treatment.
- The patent landscape features similar formulation-focused patents, emphasizing bioavailability and side effect mitigation.
- Its expiration is in 2030, well-positioned for commercial exploitation until then.
- Comparison with international patents shows differentiation through specific excipient and formulation details.
FAQs
1. Can other NSAID formulations be patented around CA2423744?
Yes. Developing formulations with different excipients, delivery methods, or therapeutic targets can avoid infringement and extend patent protection.
2. What are the risks of patent infringement for generic manufacturers?
Any formulation matching the claims involving NSAID + specified excipient could infringe. Patent validity challenges may also arise, but until resolved, rights are enforceable.
3. How broad are the claims concerning NSAID types?
Claims include a range of NSAIDs such as ibuprofen, naproxen, and ketoprofen, making the patent relevant across common drugs in this class.
4. What is the significance of the method claims?
They protect manufacturing processes, deterring competitors from copying production steps that align with the described methods.
5. Are formulations protected by this patent suitable for over-the-counter sales?
Yes, if the formulation complies with other regulatory and safety standards, the patent covers commercial OTC products.
References
[1] Canada Intellectual Property Office. (2013). Patent CA2423744. Retrieved from CIPO database.
[2] WIPO. (2022). Patent Landscape Report on NSAID Formulations.
[3] US Patent and Trademark Office. (2015). US7896543.
